Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, Before and After Treatment, in Patients with Skin and Nail Psoriasis

Overview

Journal Skin Appendage Disord

Specialty Dermatology

Date 2019 Dec 5

PMID 31799260

Citations 2

Authors

Christos Prevezas

Alexander C Katoulis

Evangelia Papadavid

Pantelis Panagakis

Dimitrios Rigopoulos

Affiliations

Soon will be listed here.

Abstract

Background: The response to treatment in patients suffering from skin and nail psoriasis is quantitatively evaluated by monitoring clinical severity and quality of life indexes, especially in the context of clinical trials. Among them, the psoriasis area severity index (PASI), the nail psoriasis area severity index (NAPSI), and the dermatology life quality index (DLQI) are currently the most widely used indexes.

Objective: To study the short-term correlation between PASI, NAPSI, and DLQI in patients with skin and nail psoriasis at baseline and 3 months after treatment initiation.

Materials And Methods: This is a 2-center prospective, observational, cross-sectional study of 40 treatment-naive patients suffering from chronic plaque psoriasis with nail involvement and requiring systemic therapy. Disease activity and quality of life were assessed at baseline and 3 months after treatment initiation by measuring PASI, NAPSI, and DLQI scores. Statistical correlations between theses indexes were investigated using the appropriate statistical tests.

Results: A positive, strong correlation was observed between DLQI and NAPSI at baseline ( = 0.579, <0.001) and at 3 months ( = 0.484, = 0.002). Similarly, a strong correlation was noted between DLQI and PASI at baseline ( = 0.496 = 0.001) and at 3 months ( = 0.401, = 0.01). Moreover, we observed a positive strong correlation ( = 0.515, = 0.001) between DLQI at baseline and NAPSI at 3 months and a moderate correlation ( = 0.433, = 0.005) between DLQI at baseline and PASI at 3 months.

Conclusion: The observed positive correlations between PASI, NAPSI, and DLQI provide further evidence in support of their simultaneous utilization in clinical studies for skin and nail psoriasis. Moreover, the predictive value of DLQI at baseline emphasizes the importance of quality of life assessment when designing a therapeutic study as well as in the everyday clinical practice.

Citing Articles

Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: Analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study.

Miyagi T, Kanai Y, Murotani K, Okubo Y, Honma M, Kobayashi S JAAD Int. 2022; 8:146-153.

PMID: 35942062 PMC: 9356143. DOI: 10.1016/j.jdin.2022.06.013.

Study of Nail Psoriasis and Dermoscopic Correlation with Dermoscopic and Modified Dermoscopic Nail Psoriasis Severity Indexes (dNAPSI and dmNAPSI).

Arora S, Paul D, Kumar R, Bhatnagar A, Arora G, Mech S Dermatol Pract Concept. 2022; 12(1):e2022010.

PMID: 35223155 PMC: 8824731. DOI: 10.5826/dpc.1201a10.

References

Paul C, Gourraud P, Bronsard V, Prey S, Puzenat E, Aractingi S . Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2010; 24 Suppl 2:2-9. DOI: 10.1111/j.1468-3083.2009.03561.x. View

Silva M, Rita Parise Fortes M, Miot L, Marques S . Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol. 2013; 88(5):760-3. PMC: 3798353. DOI: 10.1590/abd1806-4841.20132052. View

Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R . Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2017; 32(3):397-402. PMC: 5873268. DOI: 10.1111/jdv.14738. View

Rigopoulos D, Gregoriou S, Lazaridou E, Belyayeva E, Apalla Z, Makris M . Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol. 2009; 24(5):530-4. DOI: 10.1111/j.1468-3083.2009.03453.x. View

Rich P, Griffiths C, Reich K, Nestle F, Scher R, Li S . Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2007; 58(2):224-31. DOI: 10.1016/j.jaad.2007.07.042. View

Schafer I, Hacker J, Rustenbach S, Radtke M, Franzke N, Augustin M . Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2009; 20(1):62-7. DOI: 10.1684/ejd.2010.0815. View

Hesselvig J, Egeberg A, Loft N, Zachariae C, Kofoed K, Skov L . Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab. Acta Derm Venereol. 2017; 98(3):335-339. DOI: 10.2340/00015555-2833. View

Naldi L, Svensson A, Diepgen T, Elsner P, Grob J, Coenraads P . Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol. 2003; 120(5):738-41. DOI: 10.1046/j.1523-1747.2003.12145.x. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

10.

Langenbruch A, Radtke M, Gutknecht M, Augustin M . Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?. J Eur Acad Dermatol Venereol. 2018; 33(1):123-127. DOI: 10.1111/jdv.15226. View

11.

Augustin M, Kruger K, Radtke M, Schwippl I, Reich K . Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008; 216(4):366-72. DOI: 10.1159/000119415. View

12.

Hallaji Z, Babaeijandaghi F, Akbarzadeh M, Seyedi S, Barzegari M, Noormohammadpour P . A significant association exists between the severity of nail and skin involvement in psoriasis. J Am Acad Dermatol. 2011; 66(1):e12-3. DOI: 10.1016/j.jaad.2010.10.021. View

13.

de Vries A, Bogaards N, Hooft L, Velema M, Pasch M, Lebwohl M . Interventions for nail psoriasis. Cochrane Database Syst Rev. 2013; (1):CD007633. PMC: 11611064. DOI: 10.1002/14651858.CD007633.pub2. View

14.

Kyriakou A, Patsatsi A, Sotiriadis D . The agreement among the different ways of measuring NAPSI and their correlation with DLQI. J Dtsch Dermatol Ges. 2014; 12(11):1051-3. DOI: 10.1111/ddg.12432. View

15.

Mattei P, Corey K, Kimball A . Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2013; 28(3):333-7. DOI: 10.1111/jdv.12106. View

16.

Augustin M, Reich K, Blome C, Schafer I, Laass A, Radtke M . Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010; 163(3):580-5. DOI: 10.1111/j.1365-2133.2010.09831.x. View

17.

Baran R . The burden of nail psoriasis: an introduction. Dermatology. 2010; 221 Suppl 1:1-5. DOI: 10.1159/000316169. View

18.

de Jong E, Seegers B, Gulinck M, Boezeman J, van de Kerkhof P . Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996; 193(4):300-3. DOI: 10.1159/000246274. View

19.

Kim H, Lebwohl M . Biologics and Psoriasis: The Beat Goes On. Dermatol Clin. 2018; 37(1):29-36. DOI: 10.1016/j.det.2018.07.004. View

20.

Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D . Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008; 159(2):453-6. DOI: 10.1111/j.1365-2133.2008.08686.x. View